hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53

被引:98
|
作者
Kimura, T
Gotoh, M
Nakamura, Y
Arakawa, H
机构
[1] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan
[2] Fukushima Med Univ, Sch Med, Dept Surg 1, Fukushima 9601295, Japan
来源
CANCER SCIENCE | 2003年 / 94卷 / 05期
关键词
F-BOX PROTEINS; CELL-CYCLE; P53-DEPENDENT APOPTOSIS; POTENTIAL MEDIATOR; UBIQUITIN-LIGASE; BREAST-CANCER; DNA-DAMAGE; GENE; FAMILY; PHOSPHORYLATION;
D O I
10.1111/j.1349-7006.2003.tb01460.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify p53-target genes we have been using a cDNA-microarray system to assess gene expression in a p53-mutated glioblastoma cell line (U373MG) after adenovirus-mediated transfer of wild-type p53 into the p53-deficient cells. In the work reported here, expression of hCDC4b, which encodes one of the four sub-units of the SCIF (ubiquitin ligase) complex responsible for degradation of cyclin E, was dramatically up-regulated by infection with AD-p53. An electrophoretic mobility-shift assay and a chromatin immunoprecipitation assay indicated that a potential p53-binding site (p53BS) present in exon 1b of the hCDC4 gene was able to bind to p53, and a reporter assay confirmed that this p53BS had p53-dependent transcriptional activity. Expression of endogenous hCDC4b, but not the alternative transcript of this gene, hCDC4a, was induced in a p53-dependent manner in response to genotoxic stresses caused by UV irradiation and adriamycin treatment, suggesting that each transcript has a different functional role. These results suggest that hCDC4b is a previously unrecognized transcriptional target of the p53 protein, and that by negatively regulating cyclin E through induction of hCDC4b, p53 might stop cell-cycle progression at G0-G1. This would represent a novel mechanism for p53-dependent control of the cell cycle, in addition to the well-known p21(WAF1) machinery.
引用
收藏
页码:431 / 436
页数:6
相关论文
共 50 条
  • [21] FATS is a transcriptional target of p53 and associated with antitumor activity
    Zhang, Xifeng
    Zhang, Qian
    Zhang, Jun
    Qiu, Li
    Yan, Shuang-shuang
    Feng, Juling
    Sun, Yan
    Huang, Xingxu
    Lu, Karen H.
    Li, Zheng
    MOLECULAR CANCER, 2010, 9 : 244
  • [22] FATS is a transcriptional target of p53 and associated with antitumor activity
    Xifeng Zhang
    Qian Zhang
    Jun Zhang
    Li Qiu
    Shuang-shuang Yan
    Juling Feng
    Yan Sun
    Xingxu Huang
    Karen H Lu
    Zheng Li
    Molecular Cancer, 9
  • [23] Expression of Transcriptional Target of p53 Protein in Human Retinoblastoma
    Kashyap, S.
    Singh, L.
    Singh, M. K.
    Sen, S.
    Chawla, B.
    Bakhshi, S.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S345 - S345
  • [24] SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53
    Zhou, Xinyuan
    Yang, Guohua
    Huang, Rulmin
    Chen, Xiaotao
    Hu, Gengxi
    FEBS LETTERS, 2007, 581 (25): : 4943 - 4948
  • [25] DNAJB9, a novel target gene of p53, binds to p53 and inhibits the transcriptional activity
    Heo, Jee In
    Lee, Mi-Suk
    Choi, Eun-Mi
    Jeong, Yu-Jin
    Kim, Jun-Kyung
    Lee, Sam W.
    Han, Jeong A.
    Kim, Jong-Il
    FASEB JOURNAL, 2007, 21 (05): : A661 - A661
  • [26] CYFIP2, a direct p53 target, is leptomycin-B sensitive
    Jackson, Roger S., II
    Cho, Yong-Jig
    Stein, Susanne
    Liang, Peng
    CELL CYCLE, 2007, 6 (01) : 95 - 103
  • [27] Tetramerization of p53 is not required for p53-dependent repression of cyclin B expression
    Tamiso, Emily
    Levesque, Aime
    CANCER RESEARCH, 2009, 69
  • [28] A ribonucleotide reductase gene is a transcriptional target of p53 and p73
    Nakano, K
    Bálint, É
    Ashcroft, M
    Vousden, KH
    ONCOGENE, 2000, 19 (37) : 4283 - 4289
  • [29] A ribonucleotide reductase gene is a transcriptional target of p53 and p73
    Katsunori Nakano
    Éva Bálint
    Margaret Ashcroft
    Karen H Vousden
    Oncogene, 2000, 19 : 4283 - 4289
  • [30] Gfi1 as a regulator of p53 and a therapeutic target for ALL
    Khandanpour, Cyrus
    Moeroey, Tarik
    ONCOTARGET, 2013, 4 (03) : 374 - 375